Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes

Y. C. Hwang, M. Kang, C. W. Ahn, J. S. Park, Sei-Hyun Baik, D. J. Chung, H. C. Jang, K. A. Kim, I. K. Lee, K. W. Min, M. Nam, T. S. Park, S. M. Son, Y. A. Sung, J. T. Woo, K. S. Park, M. K. Lee

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aim:s: The study investigated the clinical equivalence in reducing haemoglobin A1c (A1C) between glimepiride/metformin sustained release (GM-SR) 2/500 mg, a fixed-dose combination, once daily and glimepiride/metformin (GM) 1/250 mg, a fixed-dose combination, twice daily in patients with type 2 diabetes (T2D). Methods: A multicentre, randomised, double-blind, double-dummy study was conducted in 14 hospitals in Korea. Inclusion criteria were age 30-75 years, T2D diagnosis no longer than 10 years previously, A1C between 7% and 10%, and body mass index < 40 kg/m2. A total of 207 subjects were randomised into the GM-SR group (n = 101) or the GM group (n = 106). Participants were assessed at baseline, 8 weeks and 16 weeks after treatment. Results: After 16 weeks treatment, no difference in baseline-adjusted changes of A1C (primary efficacy variable) was observed between the two groups (-0.59% for GM-SR group vs. -0.61% for GM group, 95% CI: -0.17 to 0.21; p = 0.84). In addition, there were no significant differences in secondary efficacy parameters between the two groups, including changes in A1C up to week 8, changes in fasting plasma glucose (FPG) and 2-h-postprandial plasma glucose up to week 8 and week 16, response rate, drug compliance and hypoglycaemic events. However, there was a difference in baseline-adjusted changes of FPG between the two groups (-1.01 mmol/l for GM-SR group vs. -1.52 mmol/l for GM group, p = 0.01 in the intention to treat set). Conclusions: GM-SR 2/500 mg once daily was as effective as GM 1/250 mg twice daily in lowering A1C. In addition, no difference was noted in hypoglycaemic events between the two groups.

Original languageEnglish
Pages (from-to)236-243
Number of pages8
JournalInternational Journal of Clinical Practice
Volume67
Issue number3
DOIs
Publication statusPublished - 2013 Mar 1

Fingerprint

glimepiride
Metformin
Type 2 Diabetes Mellitus
Safety
Hypoglycemic Agents
Glucose
Fasting

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes. / Hwang, Y. C.; Kang, M.; Ahn, C. W.; Park, J. S.; Baik, Sei-Hyun; Chung, D. J.; Jang, H. C.; Kim, K. A.; Lee, I. K.; Min, K. W.; Nam, M.; Park, T. S.; Son, S. M.; Sung, Y. A.; Woo, J. T.; Park, K. S.; Lee, M. K.

In: International Journal of Clinical Practice, Vol. 67, No. 3, 01.03.2013, p. 236-243.

Research output: Contribution to journalArticle

Hwang, YC, Kang, M, Ahn, CW, Park, JS, Baik, S-H, Chung, DJ, Jang, HC, Kim, KA, Lee, IK, Min, KW, Nam, M, Park, TS, Son, SM, Sung, YA, Woo, JT, Park, KS & Lee, MK 2013, 'Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes', International Journal of Clinical Practice, vol. 67, no. 3, pp. 236-243. https://doi.org/10.1111/ijcp.12071
Hwang, Y. C. ; Kang, M. ; Ahn, C. W. ; Park, J. S. ; Baik, Sei-Hyun ; Chung, D. J. ; Jang, H. C. ; Kim, K. A. ; Lee, I. K. ; Min, K. W. ; Nam, M. ; Park, T. S. ; Son, S. M. ; Sung, Y. A. ; Woo, J. T. ; Park, K. S. ; Lee, M. K. / Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes. In: International Journal of Clinical Practice. 2013 ; Vol. 67, No. 3. pp. 236-243.
@article{3f13182b046e4113bd295ce4a429547f,
title = "Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes",
abstract = "Aim:s: The study investigated the clinical equivalence in reducing haemoglobin A1c (A1C) between glimepiride/metformin sustained release (GM-SR) 2/500 mg, a fixed-dose combination, once daily and glimepiride/metformin (GM) 1/250 mg, a fixed-dose combination, twice daily in patients with type 2 diabetes (T2D). Methods: A multicentre, randomised, double-blind, double-dummy study was conducted in 14 hospitals in Korea. Inclusion criteria were age 30-75 years, T2D diagnosis no longer than 10 years previously, A1C between 7{\%} and 10{\%}, and body mass index < 40 kg/m2. A total of 207 subjects were randomised into the GM-SR group (n = 101) or the GM group (n = 106). Participants were assessed at baseline, 8 weeks and 16 weeks after treatment. Results: After 16 weeks treatment, no difference in baseline-adjusted changes of A1C (primary efficacy variable) was observed between the two groups (-0.59{\%} for GM-SR group vs. -0.61{\%} for GM group, 95{\%} CI: -0.17 to 0.21; p = 0.84). In addition, there were no significant differences in secondary efficacy parameters between the two groups, including changes in A1C up to week 8, changes in fasting plasma glucose (FPG) and 2-h-postprandial plasma glucose up to week 8 and week 16, response rate, drug compliance and hypoglycaemic events. However, there was a difference in baseline-adjusted changes of FPG between the two groups (-1.01 mmol/l for GM-SR group vs. -1.52 mmol/l for GM group, p = 0.01 in the intention to treat set). Conclusions: GM-SR 2/500 mg once daily was as effective as GM 1/250 mg twice daily in lowering A1C. In addition, no difference was noted in hypoglycaemic events between the two groups.",
author = "Hwang, {Y. C.} and M. Kang and Ahn, {C. W.} and Park, {J. S.} and Sei-Hyun Baik and Chung, {D. J.} and Jang, {H. C.} and Kim, {K. A.} and Lee, {I. K.} and Min, {K. W.} and M. Nam and Park, {T. S.} and Son, {S. M.} and Sung, {Y. A.} and Woo, {J. T.} and Park, {K. S.} and Lee, {M. K.}",
year = "2013",
month = "3",
day = "1",
doi = "10.1111/ijcp.12071",
language = "English",
volume = "67",
pages = "236--243",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes

AU - Hwang, Y. C.

AU - Kang, M.

AU - Ahn, C. W.

AU - Park, J. S.

AU - Baik, Sei-Hyun

AU - Chung, D. J.

AU - Jang, H. C.

AU - Kim, K. A.

AU - Lee, I. K.

AU - Min, K. W.

AU - Nam, M.

AU - Park, T. S.

AU - Son, S. M.

AU - Sung, Y. A.

AU - Woo, J. T.

AU - Park, K. S.

AU - Lee, M. K.

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Aim:s: The study investigated the clinical equivalence in reducing haemoglobin A1c (A1C) between glimepiride/metformin sustained release (GM-SR) 2/500 mg, a fixed-dose combination, once daily and glimepiride/metformin (GM) 1/250 mg, a fixed-dose combination, twice daily in patients with type 2 diabetes (T2D). Methods: A multicentre, randomised, double-blind, double-dummy study was conducted in 14 hospitals in Korea. Inclusion criteria were age 30-75 years, T2D diagnosis no longer than 10 years previously, A1C between 7% and 10%, and body mass index < 40 kg/m2. A total of 207 subjects were randomised into the GM-SR group (n = 101) or the GM group (n = 106). Participants were assessed at baseline, 8 weeks and 16 weeks after treatment. Results: After 16 weeks treatment, no difference in baseline-adjusted changes of A1C (primary efficacy variable) was observed between the two groups (-0.59% for GM-SR group vs. -0.61% for GM group, 95% CI: -0.17 to 0.21; p = 0.84). In addition, there were no significant differences in secondary efficacy parameters between the two groups, including changes in A1C up to week 8, changes in fasting plasma glucose (FPG) and 2-h-postprandial plasma glucose up to week 8 and week 16, response rate, drug compliance and hypoglycaemic events. However, there was a difference in baseline-adjusted changes of FPG between the two groups (-1.01 mmol/l for GM-SR group vs. -1.52 mmol/l for GM group, p = 0.01 in the intention to treat set). Conclusions: GM-SR 2/500 mg once daily was as effective as GM 1/250 mg twice daily in lowering A1C. In addition, no difference was noted in hypoglycaemic events between the two groups.

AB - Aim:s: The study investigated the clinical equivalence in reducing haemoglobin A1c (A1C) between glimepiride/metformin sustained release (GM-SR) 2/500 mg, a fixed-dose combination, once daily and glimepiride/metformin (GM) 1/250 mg, a fixed-dose combination, twice daily in patients with type 2 diabetes (T2D). Methods: A multicentre, randomised, double-blind, double-dummy study was conducted in 14 hospitals in Korea. Inclusion criteria were age 30-75 years, T2D diagnosis no longer than 10 years previously, A1C between 7% and 10%, and body mass index < 40 kg/m2. A total of 207 subjects were randomised into the GM-SR group (n = 101) or the GM group (n = 106). Participants were assessed at baseline, 8 weeks and 16 weeks after treatment. Results: After 16 weeks treatment, no difference in baseline-adjusted changes of A1C (primary efficacy variable) was observed between the two groups (-0.59% for GM-SR group vs. -0.61% for GM group, 95% CI: -0.17 to 0.21; p = 0.84). In addition, there were no significant differences in secondary efficacy parameters between the two groups, including changes in A1C up to week 8, changes in fasting plasma glucose (FPG) and 2-h-postprandial plasma glucose up to week 8 and week 16, response rate, drug compliance and hypoglycaemic events. However, there was a difference in baseline-adjusted changes of FPG between the two groups (-1.01 mmol/l for GM-SR group vs. -1.52 mmol/l for GM group, p = 0.01 in the intention to treat set). Conclusions: GM-SR 2/500 mg once daily was as effective as GM 1/250 mg twice daily in lowering A1C. In addition, no difference was noted in hypoglycaemic events between the two groups.

UR - http://www.scopus.com/inward/record.url?scp=84874113416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874113416&partnerID=8YFLogxK

U2 - 10.1111/ijcp.12071

DO - 10.1111/ijcp.12071

M3 - Article

C2 - 23336668

AN - SCOPUS:84874113416

VL - 67

SP - 236

EP - 243

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 3

ER -